Skip to main content

Table 1 Synergistic 2-agent combinations

From: Inference of synergy/antagonism between anticancer drugs from the pooled analysis of clinical trials

Agent 1 Agent 2 Standard of care* Expected ORR 1 Observed ORR 0 p synergy Cancer subtype
Docetaxel Doxorubicin Yes 40 65 7.70E-43 Breast cancer
Oxaliplatin 5-fluorouracil Yes 25 52 1.82E-17 Colorectal, gastric cancer
Irinotecan Etoposide No 19 66 4.98E-13 Lung cancer
Doxorubicin Ifosfamide Yes 19 48 1.20E-09 Gynecologic, soft tissue sarcoma
Bortezomib Thalidomide Yes 56 100 2.13E-09 Myeloma
Capecitabine Irinotecan No 35 48 9.53E-09 Colorectal, gastric, lung cancer
S-1 Irinotecan No 33 47 1.20E-07 Colorectal, gastric, lung cancer
Oxaliplatin Doxorubicin No 27 68 1.30E-07 Ovarian cancer
Oxaliplatin Irinotecan Yes 24 52 4.30E-06 Colorectal, lung cancer
Capecitabine Radiation No 65 88 3.11E-05 Cervical cancer
Rituximab Alpha-interferon No 67 94 2.48E-04 Lymphoma
Oxaliplatin Capecitabine Yes 38 44 3.41E-03 Colorectal, gastric cancer
5-fluorouracil Irinotecan Yes 22 38 5.87E-03 Colorectal cancer
Capecitabine Alpha-interferon No 38 54 3.34E-02 Renal cancer
Fludarabine Thalidomide No 78 100 4.05E-02 Leukemia
  1. *By National Comprehensive Cancer Network (NCCN) guidelines.
  2. The combinations with an observed ORR (ORR0) that is significantly higher than the expected ORR in the absence of agent interactions (ORR1).